Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martijn van Essen

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
EJNMMI Physics|May 9, 2026
Multiple vertebrae improves precision in image-based bone marrow absorbed dose estimation in [<sup>177</sup>Lu]Lu-DOTATATE treatmentKatja Smits, Frida Westerbergh, Jens Hemmingsson, et al.
Circulation. Cardiovascular Imaging|December 28, 2021
Somatostatin Receptor Positron Emission Tomography/Computed Tomography in Giant Cell Myocarditis: A Promising Approach to Molecular Myocardial Inflammation ImagingChristian L Polte, Entela Bollano, Anders Oldfors, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Alzheimer's Imaging ConsortiumStamatia Karagianni, Alexis Moscoso Rial, Martijn van Essen, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
BiomarkersStamatia Karagianni, Alexis Moscoso Rial, Martijn van Essen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 4, 2006
Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanomaMartijn van Essen, Eric P Krenning, Peter P Kooij, et al.
Seminars in Nuclear Medicine|February 2, 2010
Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumorsDik J Kwekkeboom, Wouter W de Herder, Casper H J van Eijck, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|January 27, 2021
Incidental cardiac findings on somatostatin receptor PET/CT: What do they indicate and are they of clinical relevance?Emanuele Bobbio, Anna Dudás, Anders Bergström, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 23, 2008
Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotateBart de Keizer, Maarten O van Aken, Richard A Feelders, et al.
Endocrine-Related Cancer|December 10, 2009
Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumorsDik J Kwekkeboom, Boen L Kam, Martijn van Essen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2008
Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survivalDik J Kwekkeboom, Wouter W de Herder, Boen L Kam, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
EJNMMI Physics|May 9, 2026
Multiple vertebrae improves precision in image-based bone marrow absorbed dose estimation in [<sup>177</sup>Lu]Lu-DOTATATE treatmentKatja Smits, Frida Westerbergh, Jens Hemmingsson, et al.
Circulation. Cardiovascular Imaging|December 28, 2021
Somatostatin Receptor Positron Emission Tomography/Computed Tomography in Giant Cell Myocarditis: A Promising Approach to Molecular Myocardial Inflammation ImagingChristian L Polte, Entela Bollano, Anders Oldfors, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Alzheimer's Imaging ConsortiumStamatia Karagianni, Alexis Moscoso Rial, Martijn van Essen, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
BiomarkersStamatia Karagianni, Alexis Moscoso Rial, Martijn van Essen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 4, 2006
Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanomaMartijn van Essen, Eric P Krenning, Peter P Kooij, et al.
Seminars in Nuclear Medicine|February 2, 2010
Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumorsDik J Kwekkeboom, Wouter W de Herder, Casper H J van Eijck, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|January 27, 2021
Incidental cardiac findings on somatostatin receptor PET/CT: What do they indicate and are they of clinical relevance?Emanuele Bobbio, Anna Dudás, Anders Bergström, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 23, 2008
Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotateBart de Keizer, Maarten O van Aken, Richard A Feelders, et al.
Endocrine-Related Cancer|December 10, 2009
Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumorsDik J Kwekkeboom, Boen L Kam, Martijn van Essen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2008
Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survivalDik J Kwekkeboom, Wouter W de Herder, Boen L Kam, et al.
Pageof 4